Shopping Cart
Remove All
Your shopping cart is currently empty
Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $297 | - | In Stock | |
| 5 mg | $788 | - | In Stock | |
| 10 mg | $1,230 | - | In Stock |
| Description | Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma. |
| In vitro | Ontuxizumab induces internalization of CD248 in a dose-dependent manner, with a reduction of 46% in surface CD248 on human dermal fibroblasts after 12 hours of treatment with concentrations ranging from 0 to 100 μg/mL[1]. |
| In vivo | In human CD248 knock-in mice, Ontuxizumab demonstrates antitumor effects when administered at a dose of 50 mg/kg via intravenous injection, given five times a day for five consecutive days[1]. |
| Synonyms | MORAb-004 |
| Molecular Weight | 146.92 kDa |
| Cas No. | 946415-62-9 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.